Australia-first supply of Trpti OEA™, a next-generation oleoylethanolamide (OEA).
OEA is an endogenous fatty acid amide, synthesised in the small intestine, and classified as a bioactive mono-unsaturated lipid mediator within the acylglycerol and N-acylethanolamine families.
LipiSperse® delivery technology to address the bioavailability limitations of standard OEA.
Trpti OEA™ research reference dose: 125 mg twice daily (250 mg per day)
